Fermenta Biotech Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fermenta Biotech Limited - overview
Established
1986
Location
Thane, Maharashtra, India
Primary Industry
Pharmaceuticals
About
Fermenta Biotech Limited is engaged in the production of Vitamin D3 and specialized Active Pharmaceutical Ingredients, providing essential solutions for various industries including pharmaceuticals, dietary supplements, and food fortification. Founded in 1986 in Thane, India, Fermenta Biotech Limited specializes in the production of Vitamin D3 and niche Active Pharmaceutical Ingredients. The company was acquired by Invascent Capital Partners in December 2010, details of which were not disclosed. The current CEO is Marcela Salazar and Prashant Nagre.
Fermenta has successfully completed 3 deals to date. Fermenta Biotech Limited specializes in producing Vitamin D3, offering it in crystalline forms, oil-based solutions, and cold water dispersible formats for various applications. The company also produces niche APIs such as Phenyramidol and Silicon Dioxide, alongside an integrated biotechnology platform for antibiotic synthesis and wastewater management. Their products are distributed in over 60 countries, serving pharmaceutical companies, dietary supplement manufacturers, and agricultural sectors.
In the most recent fiscal year of 2024, Fermenta Biotech Limited reported a revenue of USD 40. 55 mn and an EBITDA of USD 3. 55 mn, primarily generated through B2B transactions tied to long-term contracts and partnerships with various industries. Fermenta Biotech Limited is focused on introducing new variants of Vitamin D3 to meet diverse market needs, with plans to enhance its production capabilities.
The company aims to expand its presence in North America and Europe by 2025, utilizing recent funding to establish localized production facilities. The strategic acquisitions and partnerships formed through their latest deal in December 2010 will also support these initiatives.
Current Investors
InvAscent Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Water & Sewer Utilities, Waste Management, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.fermentabiotech.com
Total Amount Raised
Subscriber access only
Fermenta Biotech Limited - timeline of key events
Fermenta Biotech Limited - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,013,129,000 | 998,988,000 | 1,249,292,000 | 1,290,790,000 | 1,434,283,000 | 1,665,324,000 | 3,029,758,000 | 4,046,704,000 | 2,929,492,000 | 3,772,888,000 | - | - | - |
| % Revenue Growth (YoY) | - | (1.4%) | 25.1% | 3.3% | 11.1% | 16.1% | 81.9% | 33.6% | (27.6%) | 28.8% | - | - | - |
| EBITDA (USD) | 450,010,000 | 244,646,000 | 284,741,000 | 159,632,000 | 214,577,000 | 375,822,000 | 1,015,128,000 | 1,570,486,000 | 719,149,000 | 863,675,000 | - | - | - |
| Operating Income (USD) | 372,403,000 | 150,690,000 | 186,331,000 | 73,847,000 | 131,077,000 | 271,629,000 | 891,497,000 | 1,451,611,000 | 569,152,000 | 660,591,000 | - | - | - |
| Operating Margin | 36.8% | 15.1% | 14.9% | 5.7% | 9.1% | 16.3% | 29.4% | 35.9% | 19.4% | 17.5% | - | - | - |
| % EBITDA Margin | 44.4% | 24.5% | 22.8% | 12.4% | 15.0% | 22.6% | 33.5% | 38.8% | 24.5% | 22.9% | - | - | - |
| NET Income (USD) | 269,591,000 | 64,300,000 | 110,128,000 | 9,538,000 | 27,126,000 | 142,491,000 | 548,371,000 | 1,179,026,000 | 595,202,000 | 425,304,000 | - | - | - |
| % Net Margin | 26.6% | 6.4% | 8.8% | 0.7% | 1.9% | 8.6% | 18.1% | 29.1% | 20.3% | 11.3% | - | - | - |
Fermenta Biotech Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Fermenta Biotech Limited | - | ||||||||
| Unspecified Exit | Completed | Fermenta Biotech Limited | - | ||||||||
| Buyout | Completed | Fermenta Biotech Limited | - |
Displaying 1 - 3 of 3
Fermenta Biotech Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.